Vaxcyte, Inc. PCVX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $312.78M+29.2% | $242.06M+15.3% | $209.93M+8.1% | $194.18M+31.1% | $148.13M+10.9% | ||
| $33.07M+2.6% | $32.22M-0.7% | $32.45M+1.3% | $32.04M-1.9% | $32.66M+14.4% | ||
| $345.85M+26.1% | $274.28M+13.2% | $242.38M+7.1% | $226.22M+25.1% | $180.79M+11.5% | ||
| -$345.85M-26.1% | -$274.28M-13.2% | -$242.38M-7.1% | -$226.22M-25.1% | -$180.79M-11.5% | ||
| $25.23M-9.2% | $27.78M-6.0% | $29.55M-50.5% | $59.65M+48.8% | $40.08M+59.7% | ||
| -$320.62M-30.1% | -$246.51M-15.8% | -$212.83M-27.8% | -$166.57M-18.4% | -$140.72M-2.7% | ||
| -$2.30-27.8% | -$1.80-15.4% | -$1.56-27.9% | -$1.22-17.3% | -$1.04-2.0% | ||
| -$342.9M-28.5% | -$266.79M-11.5% | -$239.32M-7.2% | -$223.34M-25.6% | -$177.84M-11.6% | ||
| -$345.85M-26.1% | -$274.28M-13.2% | -$242.38M-7.1% | -$226.22M-25.1% | -$180.79M-11.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vaxcyte, Inc. profitable?
- Vaxcyte, Inc. is not currently profitable: it reported a net loss of $946.5M over the trailing twelve months.
- What is Vaxcyte, Inc.'s earnings per share?
- Vaxcyte, Inc.'s diluted EPS over the trailing twelve months is $-6.88.
- Where does Vaxcyte, Inc.'s income statement data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.